{"id":"NCT02822794","sponsor":"Gilead Sciences","briefTitle":"Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen","officialTitle":"A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Subjects With Chronic Genotype 1 or 2 HCV Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-25","primaryCompletion":"2017-06-02","completion":"2017-08-25","firstPosted":"2016-07-04","resultsPosted":"2018-07-03","lastUpdate":"2018-11-14"},"enrollment":117,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]},{"type":"DRUG","name":"RBV","otherNames":["REBETOL®"]}],"arms":[{"label":"SOF/VEL FDC + RBV 12 weeks","type":"EXPERIMENTAL"},{"label":"SOF/VEL FDC + RBV 24 weeks","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and ribavirin (RBV) in participants with chronic genotype 1 or 2 hepatitis C virus (HCV) infection who have previously failed a direct-acting antiviral (DAA)-containing regimen.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL+RBV 12 Weeks (GT1)","deltaMin":85.1,"sd":null},{"arm":"SOF/VEL+RBV 12 Weeks (GT2)","deltaMin":70,"sd":null},{"arm":"SOF/VEL+RBV 24 Weeks (GT1)","deltaMin":97.9,"sd":null},{"arm":"SOF/VEL+RBV 24 Weeks (GT2)","deltaMin":91.7,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG002","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":18,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":57},"commonTop":["Viral upper respiratory tract infection","Anaemia","Headache","Stomatitis","Nausea"]}}